Company Overview

Receptor Logic, Inc. is revolutionizing the field of immunology through our proprietary T-Cell Receptor mimic (TCRm) technology. Receptor Logic’s TCRm technology provides ground breaking opportunity in three business sectors through the following capabilities:

  1. Novel platform for therapeutic monoclonal antibodies (mAbs) and associated companion diagnostics;
  2. Immunology research reagents available to biomedical research oriented companies and institutions; and
  3. Assay development and implementation services supporting T-cell eliciting therapy development and regulatory potency determination.

The Receptor Logic Difference

Industry Challenge

Monoclonal antibody (mAb) therapy is remarkably effective for addressing cancer, chronic inflammatory conditions, and pathogen infections. However, to be successful, the molecular targets, i.e., biomarkers, of mAbs must be soluble proteins in the blood or exclusively present on the surface of diseased cells. Unfortunately, most disease specific biomarkers are intracellular in nature and not accessible to standard mAb therapies. The lack of available biomarkers increases competition among existing mAb products and new product launches further segments established markets and reduces financial return. Accessing new disease specific targets unlocks new disease indications to mAb therapy, paving the way for successful products.

The Receptor Logic Solution

Disease conditions result in the appearance of peptide antigens (pieces of proteins exclusively expressed in diseased cells) in the Major Histocompatibilty Complex (MHC). These MHC-peptide complexes form excellent disease specific markers that are present on the surface of diseased cells and not observed on healthy cells or tissue types. Receptor Logic exclusively offers a revolutionary type of mAb in the form of TCRm antibodies that recognize specific MHC-peptide complexes, thereby allowing soluble reagents to identify diseased cells with great specificity.

The Benefits of the Receptor Logic Solution

The binding of the TCRms to MHC-peptide complexes allows researchers to:

  • measure peptide (antigen) expression on diseased cells,
  • monitor the immune response of individuals,
  • establish the potency of immunotherapeutic agents, and
  • directly eliminate diseased cells in the individual.

These capabilities offer a modality that can simultaneously assist in disease diagnosis and patient qualification while also acting as a therapeutic agent. Such novel mAb products offer improved therapeutic options to cancer and other diseases that are inaccessible using the current repertoire of mAb biomarkers. Expanded access to new disease indications as well as addressing diseases with potential best in class therapies, opens broad commercial opportunities for Receptor Logic and its product offerings.